MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Anticoagulation in Post MI LV Thrombus Trial in Nepal

Phase 4
Recruiting
Conditions
Left Ventricular Thrombus
Myocardial Infarction
Interventions
First Posted Date
2023-04-03
Last Posted Date
2025-05-11
Lead Sponsor
Shahid Gangalal National Heart Centre
Target Recruit Count
196
Registration Number
NCT05794399
Locations
🇳🇵

Nepal Health Research Council, Kathmandu, Bagmati, Nepal

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Phase 4
Recruiting
Conditions
Anticoagulation
Coronary Endarterectomy
Interventions
First Posted Date
2023-03-23
Last Posted Date
2025-04-04
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
202
Registration Number
NCT05782270
Locations
🇨🇳

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable
Completed
Conditions
Liver Cirrhosis
Interventions
First Posted Date
2023-02-23
Last Posted Date
2025-01-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4
Registration Number
NCT05741385
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

Phase 3
Completed
Conditions
ST Segment Elevation Myocardial Infarction
Left Ventricular Thrombus
Interventions
First Posted Date
2023-01-30
Last Posted Date
2023-04-07
Lead Sponsor
Rajaie Cardiovascular Medical and Research Center
Target Recruit Count
50
Registration Number
NCT05705089
Locations
🇮🇷

Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of

🇮🇷

Tehran Heart Center, Tehran, Iran, Islamic Republic of

DIrect Oral Anticoagulation and mechaNical Aortic Valve

Phase 4
Not yet recruiting
Conditions
Aortic Valve Disease
Interventions
First Posted Date
2023-01-18
Last Posted Date
2023-01-26
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
1044
Registration Number
NCT05687448
Locations
🇫🇷

Service de Cardiologie Hôpital Lariboisière, Paris, France

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

First Posted Date
2022-12-09
Last Posted Date
2022-12-09
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
80
Registration Number
NCT05644210
Locations
🇨🇳

Qilu Hospital, Jinan, Shandong, China

Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease

Phase 4
Not yet recruiting
Conditions
Coronary Artery Aneurysm
Kawasaki Disease
Interventions
First Posted Date
2022-12-09
Last Posted Date
2025-02-14
Lead Sponsor
Children's Hospital of Fudan University
Target Recruit Count
100
Registration Number
NCT05643651
Locations
🇨🇳

Children's Hospital of Fudan University, Shanghai, Shanghai, China

A Drug Interaction Study of LY3871801 in Healthy Participants

First Posted Date
2022-11-02
Last Posted Date
2023-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
39
Registration Number
NCT05602675
Locations
🇺🇸

Covance Dallas, Dallas, Texas, United States

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Phase 2
Recruiting
Conditions
Mitral Valve Stenosis
Atrial Fibrillation
Stroke
Systemic Embolism
Interventions
First Posted Date
2022-09-14
Last Posted Date
2022-09-14
Lead Sponsor
Sung-Hwan Kim
Target Recruit Count
240
Registration Number
NCT05540587
Locations
🇰🇷

Bucheon St. Mary's hospital, Bucheon, Korea, Republic of

🇰🇷

Yeouido St. Mary's hospital, Yeongdeungpo-gu, Seoul, Korea, Republic of

🇰🇷

Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of

and more 4 locations

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-07-29
Last Posted Date
2022-11-08
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
18
Registration Number
NCT05480488
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

© Copyright 2025. All Rights Reserved by MedPath